Cencora, Inc. (COR) stock intrinsic value fair value estimate & owner earnings analysis

Cencora (formerly AmerisourceBergen) is one of three companies that distribute the large majority of prescription drugs sold in the United States, moving medicines from manufacturers to pharmacies, hospitals, physician practices, and specialty clinics on thin, fee-for-service-like margins earned on enormous volume. It also distributes animal health products (through MWI) and provides specialty logistics and regulatory consulting services internationally. About nine-tenths of revenue is generated in the United States, spread across the Northeast, Midwest, South, and West; the remainder comes mainly from the United Kingdom and other European markets, with smaller operations in Canada, the Middle East, and Asia. The business has grown steadily for a decade, with revenue compounding at roughly 10-12% a year, most recently propelled by demand for GLP-1 diabetes and weight-loss drugs (Wegovy, Zepbound, Mounjaro and similar), which added about $7.7 billion of revenue in the most recent fiscal year alone. That growth comes with a catch management has flagged directly: GLP-1 products carry lower gross margins than the rest of the portfolio, so revenue growth is not converting one-for-one into profit growth. We measure the cash the business actually generates for owners each year (operating cash flow, less the swings in receivables/inventory/payables that come from ordinary business timing, less stock-based compensation, less the capital spending needed just to maintain the current business) rather than reported accounting earnings. On that basis, owner earnings per share have grown from about $7.27 in fiscal 2016 to about $2.35 in a weak fiscal 2017 (a year of generic-drug price deflation) and back up to roughly $13.69 in fiscal 2025, with the most recent five years running $7.54, $8.52, $10.26, $10.51 and $13.69. We use the median of that five-year run, about $10.26 per share, as the normalized starting point for valuation, rather than the unusually strong final year, because owner earnings can swing year to year on the timing of payables and receivables alone. One accounting judgment worth stating plainly: since April 2022, Cencora has been paying down its share of a roughly $4.3 billion national opioid-litigation settlement, spread over 13 years (about $400-500 million a year recently, an estimated $416 million in the coming year). We have treated these payments as a real, ongoing cost of doing business, not as one of the routine working-capital swings we normalize away, because it is a genuine, scheduled cash outflow rather than a timing effect. In the one year the liability was first recorded (fiscal 2020), the up-front, non-cash charge to earnings was offset by a large add-back to cash flow, which we flagged as a one-time, non-recurring item rather than folding into the normal earnings trend. We then grew that $10.26 starting point over ten years using assumptions we can point to evidence for, discounting everything at a flat 6%, with no extra discount for risk (risk is instead reflected in the range between the cases below). Beyond ten years, because three national distributors have controlled the large majority of U.S. drug distribution for well over two decades with no evidence of that structure breaking down, we assume the current level of owner earnings persists, but we do not assume further growth beyond what we can specifically point to. In the base case, owner earnings per share grow roughly 6-8% a year, well below the roughly 30% growth actually recorded last year (which was flattered by an unusually large one-year swing in payables), reflecting continued GLP-1 and specialty-drug volume growth diluted by lower margins on those products, offset somewhat by the steady share buybacks Cencora has run for a decade (shares outstanding have fallen from about 226 million in fiscal 2016 to about 195 million in fiscal 2025). That produces a present value of roughly $298 per share. The bear case assumes growth slows to roughly the rate of inflation for the next decade. The specific, evidenced pressures behind this: Walgreens and its UK affiliate Boots together are about a quarter of Cencora's revenue, and Walgreens was taken private by Sycamore Partners in August 2025, which has already disclosed a plan to close about 1,200 U.S. stores over three years; a second large customer, Evernorth Health Services, is another 13% of revenue, and Cencora has already lost at least one specialty customer contract this year on non-renewal; the company has also written off goodwill or intangibles in three of the last seven years ($570 million in fiscal 2019, $418 million in fiscal 2024, $837 million in fiscal 2025), a pattern of overpaying for acquisitions that we treat as a real, recurring risk rather than a one-off; and a federal executive order issued in 2025 directs regulators to promote direct-to-consumer drug purchasing programs, including for the exact high-growth GLP-1 category, that could let manufacturers bypass wholesale distributors like Cencora altogether -- a concrete, dated threat to the growth story, not a hypothetical one. Together these produce a present value of roughly $185 per share. We should also note that Cencora discloses it cannot estimate the potential cost of opioid-related claims not yet covered by settlement agreements (including one state that has not settled); we have not put a number on that risk because the company itself says it cannot be estimated, but it is a real, unquantified tail risk beyond the cases above. The bull case assumes the current growth trends -- GLP-1 and specialty-drug volume, international expansion, and continued buybacks -- persist at close to their recent pace for the next several years without deterioration. That produces a present value of roughly $346 per share. Given the meaningful customer concentration and the emerging disintermediation risk around direct-to-consumer drug sales, the margin-of-safety price carries a real cushion below fair value, in the neighborhood of $205 per share or lower.